阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎126例疗效观察被引量：10

The Curative Effect Observation of Adefovir Dipivoxil for Lamivudine-resistant Chronic Hepatitis B(A Report of 126 Cases)

下载PDF

导出

摘要目的探讨阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床疗效及安全性。方法选择126例拉米夫定耐药的慢性乙型肝炎患者予以阿德福韦酯10mg/d,疗程1年。于治疗前和治疗3、6、12个月检测肝、肾功能,HBV-DNA定量,HbeAg,抗HBe,观察药物不良反应。结果治疗3、6、12个月时,HBV-DNA定量随用药时间延长逐渐下降,HBV-DNA转阴率及HBeAg阴转率随用药时间延长逐渐上升,ALT复常率随用药时间延长逐渐上升,常见不良反应有轻微乏力、右上腹不适、腹胀。结论阿德福韦酯片治疗拉米夫定耐药慢性乙型肝炎,可在病毒学及生物化学方面取得较好疗效,且安全性良好。 Objective To discuss the clinical efficacy and safety of adefovir dipivoxil for lamivudine-resistant chronic hepatitis B. Methods We chose 126 lamivudine-resistant chronic hepatitis B patients who were given to adefovir dipivoxil 10mg per day,which lasts for one year. Before treatment,and after 3,6,12 months,we detected liver function,HBV-DNA ration,HBeAg,anti-HBe,and adverse drug reactions respectively. Results With treatment, HBV-DNA ration has been gradually declining with extended medication use, HBV DNA-negative rate and clearance rate of HBeAg gradually increased with medication time,ALT normalization rate gradually rise with the drug extended,and common adverse reactions were mild weakness,right upper abdominal discomfort,and abdominal distension. Conclusion Adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B, has better efficacy in biochemistry and virology, and its safety is good.

作者朱培福

机构地区江苏省张家港市第一人民医院传染科

出处《中国现代医生》 2007年第12X期90-91,104,共3页 China Modern Doctor

关键词慢性乙型肝炎拉米夫定耐药阿德福韦酯 Chronic hepatitis B Lamivudine-resistant Adefovir Dipivoxil

分类号 R512.6 [医药卫生—内科学]

引文网络
相关文献

参考文献3

1贺新国.11166例病毒性肝炎流行病学统计分析[J].中国现代医生,2007,45(05Z):77-78. 被引量：2
2段忠辉,孟庆华.拉米夫定和阿德福韦及恩替卡韦治疗乙肝的现状和进展[J].中国全科医学,2007,10(1):67-71. 被引量：20
3中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14010

二级参考文献25

1Beckebaum S, Malago M, Dirsch O, et al. Efficacy of combined lamvudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation [ J]. Clin Transplant, 2003,17: 554-559.
2El - Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States [J]. N Engl J Med, 1999, 340:745 -750.
3Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA andalanine aminotransferase [J]. Gut, 2003, 52: 420-424.
4Dando T, Plosker G. Adefovir dipivoxil a review of its use in chronic hepatitis B [J]. Drugs, 2003, 63:2215-2234.
5Chang TT, Chao YC. Sustained response off- treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside - naive,HBeAg ( + ) patients: 24 - week follow - up results of phase 3 study-022 [ C]. 15th Asian Pacific Association for the Study of the Liver,2005 : 191.
6Jonas MM, Kelly DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B [J]. N Engl J Med, 2002, 346:1706 - 1713.
7Yao GB, Chen CW, Lun W, et al. Entecavir is superior to lamivudine for the treatment of chronic heptatitis B: results of the phase 3 study ETV -023 in nucleoside- naive patients [ C]. 15th Asian Pacific Association for the Study of the Liver, 2005 : 147.
8Shirotor Y, Omata M, Han KH, et al. Entecavir versus lamivudine and pcgylated interferon versus lamivudine: insight for troating chronic heptatitis B [ C ]. 15th Asian Pacific Association for the Study of the Liver, 2005: 249.
9Yao GB, Zhou XQ, Xu DZ, et al. A randomized, placebo -controlled study ( etv -056) in china of the efficacy and safety of entecavir(ETV) in chronic heptatitis B (CHB) patients who have lamivudine(LVD) therapy [ C]. 15th Asian Pacific Association for the Study ofthe Liver, 2005: 203.
10Hagmann S, Chung M, Rochford G, et al. Response to lamivudinetreatment in children with chronic hepatitis B virus infection [ J ].Clinical infectious diseases, 2003, 37 : 1434 - 1440.